Program
Recombinant Oncolytic Adenovirus 5 Encoding Non-secreting Interleukin-12 BioTTT001
Its studies are mostly in Glioma · Breast Neoplasms · Adenoviridae Infections, led by Beijing Bio-Targeting Therapeutics Technology.
Drug pageRecombinant Oncolytic Adenovirus 5 Encoding Non-secreting Interleukin-12 BioTTT001: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Beijing Bio-Targeting Therapeutics Technology | 32 open or running | phase 2since Jan 2, 2025 | Nov 27, 2023 | Jul 31, 2027phase 2 · NCT06763965 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 27, 2023First study: phase 1 study in Adenoviridae InfectionsFirst studyNCT06215846 · 12 planned · China
- Jan 2, 2025Phase 2 study in GliomaNCT06763965 · 30 planned · China
- Aug 25, 2025Phase 1 study in Locally Advanced Breast Cancer (LABC)NCT07150767 · China
Ahead
- Jul 31, 2027Primary completion: phase 2 study in GliomaNCT06763965
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07150767Locally Advanced Breast Cancer (LABC) · China | 1 | Withdrawn | Mar 26, 2027 | 0 |
| NCT06763965Glioma · China | 2 | By invitation | Jul 31, 2027 | 30 |
| NCT06215846Adenoviridae Infections · China | 1 | By invitation | May 30, 2026 | 12 |
How it is read
Names in the registry
- “BioTTT001 injection”, 3 entries
Conditions, from the studies’ own filings
- Glioma, 1 study
- Breast Neoplasms, 1 study
- Adenoviridae Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.